| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 155 | 169 | 172 | 174 | 182 | 187 | 205 | 193 | 206 | 242 | 246 | 259 | 203 | 258 | 238 | 257 | 222 | 294 | 270 | 415 | 365 | 421 | 395 | 390 | 465 | 315 | 458 | 336 | 301 |
| Expenses | 145 | 154 | 156 | 154 | 162 | 161 | 176 | 162 | 172 | 201 | 199 | 219 | 175 | 215 | 204 | 217 | 193 | 224 | 215 | 287 | 266 | 280 | 272 | 278 | 316 | 249 | 311 | 277 | 258 |
| EBITDA | 10 | 15 | 16 | 20 | 19 | 26 | 29 | 32 | 35 | 42 | 47 | 40 | 28 | 43 | 34 | 40 | 29 | 70 | 55 | 128 | 99 | 141 | 123 | 112 | 149 | 67 | 146 | 59 | 42 |
| Operating Profit % | 6 % | 9 % | 9 % | 11 % | 10 % | 13 % | 14 % | 16 % | 16 % | 17 % | 19 % | 10 % | 13 % | 17 % | 14 % | 15 % | 13 % | 24 % | 20 % | 29 % | 27 % | 33 % | 31 % | 28 % | 28 % | 20 % | 22 % | 16 % | 12 % |
| Depreciation | 6 | 6 | 7 | 7 | 8 | 8 | 8 | 8 | 9 | 9 | 10 | 11 | 12 | 12 | 13 | 12 | 13 | 13 | 13 | 14 | 14 | 15 | 15 | 17 | 16 | 16 | 16 | 17 | 20 |
| Interest | 4 | 4 | 3 | 5 | 4 | 5 | 6 | 7 | 5 | 4 | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 4 | 2 | 4 | 4 | 4 | 3 | 1 | 2 | 2 | 5 |
| Profit Before Tax | 1 | 5 | 6 | 8 | 8 | 12 | 16 | 17 | 20 | 29 | 32 | 24 | 12 | 28 | 18 | 24 | 14 | 53 | 39 | 110 | 83 | 122 | 105 | 92 | 130 | 49 | 128 | 39 | 18 |
| Tax | 0 | 1 | 1 | 2 | 2 | 4 | 5 | 27 | 5 | 7 | 5 | 7 | 3 | 7 | 5 | 3 | 4 | 15 | 8 | 26 | 21 | 32 | 23 | 25 | 32 | 17 | 26 | 12 | 4 |
| Net Profit | 1 | 5 | 5 | 7 | 6 | 9 | 11 | -9 | 15 | 21 | 27 | 17 | 9 | 20 | 13 | 22 | 10 | 39 | 31 | 85 | 62 | 89 | 81 | 68 | 98 | 33 | 102 | 28 | 14 |
| EPS in ₹ | 0.44 | 3.55 | 3.66 | 5.17 | 4.45 | 6.77 | 8.66 | -7.25 | 11.82 | 16.71 | 20.84 | 13.48 | 6.81 | 15.88 | 10.08 | 16.97 | 7.77 | 29.97 | 23.81 | 65.90 | 48.23 | 69.56 | 63.44 | 52.66 | 76.28 | 25.60 | 79.18 | 21.67 | 10.83 |
Neuland Laboratories
Neuland Laboratories
16,049.00
+495.00
(3.18%)
Market Cap
20,590.69 Cr
EPS
202.74
PE Ratio
151.49
Dividend Yield
0.08 %
Industry
Healthcare52 Week High
18,100.00
52 Week Low
10,190.70
PB Ratio
13.10
Debt to Equity
0.09
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from3 analysts
Company News
View All News
Neuland Lab has commenced commercial production following the expansion of its Unit 3 manufacturing facility located in Telangana. The company has successfully started operations at the expanded capacity.
Neuland Laboratories has issued a postal ballot notice seeking shareholder approval through remote e-voting for the appointment of Dr. Ravi Shankar Gopinath (DIN: 00803847) as an Independent Director. The Board appointed him as Additional Director effective August 1, 2025, based on recommendations from the Nomination and Remuneration Committee. The proposed appointment is for a five-year term from August 1, 2025 to July 31, 2030, and he will not be liable to retire by rotation. Dr. Gopinath, aged 59, holds a Ph.D. in Chemical Engineering and has extensive experience including leadership roles at TCS, Geometric Ltd., AVEVA plc, and Schneider Electric. The e-voting period runs from August 28, 2025 (9:00 AM IST) to September 26, 2025 (5:00 PM IST). Results will be announced by September 28, 2025. The resolution requires approval by special resolution, and NSDL is providing the remote e-voting facility.
Neuland Laboratories Reports 32% Revenue Decline in Q1FY26, Expects Strong Growth Recovery
Aug 04, 2025
Aug 04, 2025Neuland Laboratories reported total income of Rs. 300.6 crores for Q1FY26, a 32.4% decrease compared to Rs. 444 crores in the same period last year. EBITDA stood at Rs. 42.1 crores with a margin of 14.4%, while profit after tax dropped to Rs. 13.7 crores from Rs. 98.3 crores in Q1FY25. The company attributed the decline to the uneven nature of order flows in their CDMO and specialty GDS business. Working capital deteriorated to 145 days of sales with negative free cash flow of Rs. 66 crores. Despite the weak start, management remains confident of achieving strong growth in FY26, expecting commercialization of another CMS molecule and commercial production from their Unit 3 facility later this fiscal year. The company invested Rs. 79 crores in CAPEX during the quarter and expects total CAPEX of Rs. 250 crores for FY26. Management emphasized their 3-5 year CAGR target of 20% and highlighted growing customer interest in their peptide capabilities, with the new peptide facility expected to be completed next financial year.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,616.60 | #1 3,87,876.49 | 33.67 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 49.00 | |
6,026.50 | 1,59,984.64 | 69.22 | 9,712.00 | 18.67 | 2,191 | 26.74 | 39.47 | |
1,574.60 | 1,27,181.67 | 23.38 | 28,409.50 | 7.12 | 5,291 | 9.88 | 52.08 | |
3,566.20 | 1,20,696.41 | 60.00 | 11,539.40 | 6.99 | 1,911 | 19.91 | 48.74 | |
1,316.70 | 1,09,887.98 | #1 19.15 | 33,741.20 | 16.73 | 5,725 | 1.26 | 60.35 | |
2,579.60 | 1,06,467.51 | 56.70 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 58.41 | |
1,044.75 | 1,05,126.30 | 22.52 | 23,511.00 | 18.55 | 4,615 | 2.60 | 68.18 | |
2,043.40 | 93,321.15 | 24.55 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 59.44 | |
30,980.00 | 65,830.34 | 45.32 | 6,684.70 | 9.64 | 1,414 | 11.55 | 39.39 | |
5,448.00 | 65,139.01 | 28.38 | 13,458.30 | 3.70 | 2,216 | 21.39 | 63.73 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
-4.70 %
Net Income Growth
-13.33 %
Cash Flow Change
21.52 %
ROE
-27.06 %
ROCE
-30.03 %
EBITDA Margin (Avg.)
-24.07 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,384 | 1,580 | 1,833 | 2,180 |
| Fixed Assets | 123 | 139 | 466 | 475 | 542 | 653 | 716 | 767 | 758 | 824 | 955 |
| Current Assets | 316 | 314 | 375 | 447 | 454 | 515 | 550 | 581 | 761 | 921 | 1,140 |
| Capital Work in Progress | 42 | 41 | 20 | 126 | 105 | 24 | 17 | 21 | 41 | 46 | 48 |
| Investments | 0 | 0 | 8 | 8 | 8 | 8 | 7 | 4 | 1 | 1 | 109 |
| Other Assets | 347 | 345 | 393 | 463 | 477 | 547 | 585 | 592 | 781 | 962 | 1,068 |
| Total Liabilities | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,384 | 1,580 | 1,833 | 2,180 |
| Current Liabilities | 295 | 268 | 286 | 367 | 327 | 358 | 369 | 363 | 439 | 428 | 466 |
| Non Current Liabilities | 55 | 69 | 54 | 146 | 104 | 163 | 170 | 180 | 147 | 122 | 189 |
| Total Equity | 162 | 187 | 546 | 558 | 699 | 710 | 787 | 841 | 994 | 1,283 | 1,525 |
| Reserve & Surplus | 152 | 178 | 537 | 549 | 686 | 697 | 774 | 828 | 981 | 1,270 | 1,512 |
| Share Capital | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 0 | 1 | -4 | -0 | 5 | 3 | -9 | 3 | 40 | 42 | 44 |
| Investing Activities | -14 | -20 | -42 | -116 | -77 | -49 | -85 | -95 | -61 | -150 | -298 |
| Operating Activities | 13 | 45 | 39 | 11 | 70 | 57 | 189 | 60 | 237 | 261 | 317 |
| Financing Activities | 1 | -24 | -0 | 105 | 12 | -6 | -114 | 38 | -136 | -69 | 25 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 36.22 % | 36.22 % | 36.22 % | 36.22 % | 36.22 % | 36.22 % | 36.22 % | 36.14 % | 36.14 % | 36.03 % | 35.97 % | 32.80 % | 32.74 % | 32.72 % | 32.64 % | 32.68 % | 32.68 % | 32.68 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 21.57 % | 22.69 % | 24.44 % | 25.72 % | 26.46 % | 23.86 % | 22.11 % | 21.69 % |
| DIIs | 0.87 % | 0.04 % | 0.80 % | 0.80 % | 0.80 % | 0.80 % | 6.58 % | 6.55 % | 7.10 % | 6.76 % | 6.99 % | 6.03 % | 6.54 % | 6.39 % | 6.38 % | 9.08 % | 10.97 % | 11.57 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.44 % | 0.46 % | 0.40 % | 0.40 % | 0.40 % | 0.40 % | 0.40 % | 0.40 % | 0.40 % | 0.40 % | 0.40 % | 0.40 % |
| Public / Retail | 34.06 % | 36.62 % | 33.19 % | 32.84 % | 32.43 % | 33.25 % | 31.03 % | 30.09 % | 29.86 % | 29.01 % | 27.86 % | 29.51 % | 27.97 % | 27.05 % | 26.50 % | 26.05 % | 25.86 % | 25.55 % |
| Others | 28.85 % | 27.12 % | 29.80 % | 30.15 % | 30.56 % | 29.74 % | 25.73 % | 26.76 % | 26.51 % | 27.80 % | 7.21 % | 8.57 % | 7.91 % | 7.71 % | 7.61 % | 7.93 % | 7.99 % | 8.12 % |
| No of Share Holders | 0 | 22,412 | 34,978 | 34,332 | 32,426 | 32,257 | 31,976 | 30,600 | 26,948 | 25,223 | 26,824 | 27,723 | 28,616 | 29,077 | 34,567 | 39,315 | 39,333 | 42,419 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 2 | 5 | 5 | 10 | 14 | 12 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.1 | 0.49 | 0.28 | 0.16 | 0.12 | 0.07 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 01 Jul 2021 |  Dividend | ₹ 3.00 /share | 29 Jun 2021 | 2,692.70 | 2,142.20 |
| 15 Jul 2022 | Dividend | ₹ 5.00 /share | 14 Jul 2022 | 1,334.25 | 1,298.00 |
| 12 Jul 2023 | Dividend | ₹ 10.00 /share | 11 Jul 2023 | 2,115.25 | 2,998.80 |
| 13 Jul 2024 | Dividend | ₹ 14.00 /share | 12 Jul 2024 | 7,146.85 | 8,094.80 |
| 31 Jul 2024 |  Annual General Meeting | NA | 31 Jul 2024 | 7,146.85 | 9,051.20 |
| 06 Nov 2024 |  Quarterly Result Announcement | NA | 06 Nov 2024 | 16,250.70 | 15,858.20 |
| 10 Feb 2025 | Quarterly Result Announcement | NA | 10 Feb 2025 | 13,869.35 | 14,247.35 |
| 15 May 2025 | Quarterly Result Announcement | NA | 15 May 2025 | 12,820.80 | 12,472.30 |
| 18 Jul 2025 | Dividend | ₹ 12.00 /share | 18 Jul 2025 | 12,472.30 | 14,496.35 |
| 30 Jul 2025 | Annual General Meeting | NA | 30 Jul 2025 | 12,472.30 | 13,849.10 |
| 31 Jul 2025 | Quarterly Result Announcement | NA | 31 Jul 2025 | 12,306.00 | 13,914.00 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation2 days ago
2 days agoRe-Lodgement Of Transfer Request Of Physical Shares2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationSep 02, 2025
Sep 02, 2025Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateAug 30, 2025
Aug 30, 2025Intimation Under Regulation 30 Of SEBI Listing RegulationsAug 30, 2025
Aug 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 27, 2025
Aug 27, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotAug 26, 2025
Aug 26, 2025Re-Lodgement Of Transfer Requests Of Physical SharesAug 23, 2025
Aug 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 20, 2025
Aug 20, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 12, 2025
Aug 12, 2025Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 04, 2025
Aug 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 31, 2025
Jul 31, 2025Update On Outcome Of Board Meeting And Change In Directorate Disclosures Regarding Appointment Of Additional DirectorJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 31, 2025
Jul 31, 2025Unaudited Financial Results For Quarter Ended June 30 2025Jul 31, 2025
Jul 31, 2025Board Meeting Outcome for Unaudited Financial Results For Quarter Ended June 30 2025Jul 31, 2025
Jul 31, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 30, 2025
Jul 30, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 26, 2025
Jul 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 25, 2025
Jul 25, 2025Addendum To The Notice Of 41St Annual General MeetingJul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 15, 2025
Jul 15, 2025Disclosure Under Regulation 30 Of SEBI Listing RegulationsJul 15, 2025
Jul 15, 2025Clarification sought from Neuland Laboratories LtdJul 15, 2025
Jul 15, 2025Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter Ended June 30 2025Jul 14, 2025
Jul 14, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Jul 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 05, 2025
Jul 05, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 04, 2025
Jul 04, 2025Notice Of 41St Annual General MeetingJul 04, 2025
Jul 04, 2025Reg. 34 (1) Annual Report.Jul 04, 2025
Jul 04, 2025Disclosure Under Regulation 30 Of SEBI Listing RegulationsJun 28, 2025
Jun 28, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Credit RatingJun 21, 2025
Jun 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 19, 2025
Jun 19, 2025Disclosure Under Regulation 30 Of SEBI Listing RegulationsJun 17, 2025
Jun 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 17, 2025
Jun 17, 2025Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateJun 17, 2025
Jun 17, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 11, 2025
Jun 11, 2025Compliance Certificate Pursuant To SEBI Exemption Order Dated January 3 2025 For The Financial Year Ended March 31 2025Jun 10, 2025
Jun 10, 2025Clarification sought from Neuland Laboratories LtdJun 09, 2025
Jun 09, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 19, 2025
May 19, 2025Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateMay 19, 2025
May 19, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 19, 2025
May 19, 2025Technical Indicators
RSI(14)
Neutral 72.96
ATR(14)
Volatile 551.28
STOCH(9,6)
Overbought 80.49
STOCH RSI(14)
Overbought 94.17
MACD(12,26)
Bullish 160.90
ADX(14)
Strong Trend 27.19
UO(9)
Bearish 63.61
ROC(12)
Uptrend And Accelerating 14.98
WillR(14)
Overbought -7.44
Mutual Fund Holdings
Motilal Oswal Business Cycle Fund Direct-Growth 
HSBC Small Cap Fund Direct-Growth 
ICICI Prudential Flexicap Fund Direct - Growth 
Mahindra Manulife Small Cap Fund Direct - Growth 
Bajaj Finserv Flexi Cap Fund Direct-Growth 
Bajaj Finserv Small Cap Fund Direct-Growth 
WhiteOak Capital Flexi Cap Fund Direct - Growth 
Mirae Asset Small Cap Fund Direct-Growth 
Bandhan Small Cap Fund Direct-Growth 
LIC MF Dividend Yield Fund Direct - Growth 
ITI Small Cap Fund Direct-Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
JM ELSS Tax Saver Fund Direct Plan-Growth 
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
